About uniQure N.V.
https://www.uniqure.comuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
CEO
Matthew Craig Kapusta CPA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 54
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Stifel
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Mizuho
Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
FMR LLC
Shares:6.06M
Value:$135.43M
AVORO CAPITAL ADVISORS LLC
Shares:4.44M
Value:$99.33M
RTW INVESTMENTS, LP
Shares:4.42M
Value:$98.9M
Summary
Showing Top 3 of 263
About uniQure N.V.
https://www.uniqure.comuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.7M ▼ | $54.34M ▲ | $-80.53M ▼ | -2.18K% ▼ | $-1.38 ▼ | $-51.55M ▼ |
| Q2-2025 | $5.26M ▲ | $48.47M ▲ | $-37.72M ▲ | -716.82% ▲ | $-0.69 ▲ | $-18.07M ▲ |
| Q1-2025 | $1.57M ▼ | $40.7M ▼ | $-43.64M ▲ | -2.78K% ▼ | $-0.82 ▲ | $-23.5M ▲ |
| Q4-2024 | $5.22M ▲ | $50.43M ▲ | $-73.26M ▼ | -1.4K% ▲ | $-1.5 ▼ | $-53.17M ▼ |
| Q3-2024 | $2.29M | $41.49M | $-44.38M | -1.94K% | $-0.91 | $-24.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $694.25M ▲ | $888.38M ▲ | $659.64M ▲ | $228.75M ▲ |
| Q2-2025 | $376.97M ▼ | $584.89M ▼ | $588.89M ▲ | $-4M ▼ |
| Q1-2025 | $409.01M ▲ | $605.4M ▲ | $571.72M ▲ | $33.69M ▲ |
| Q4-2024 | $367.52M ▼ | $556.54M ▼ | $563.29M ▼ | $-6.75M ▼ |
| Q3-2024 | $435.24M | $645.81M | $589.99M | $55.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-80.53M ▼ | $-16.4M ▲ | $26.58M ▼ | $332.24M ▲ | $343.28M ▲ | $-16.33M ▲ |
| Q2-2025 | $-37.72M ▲ | $-39.9M ▲ | $73.07M ▲ | $44K ▼ | $36.61M ▼ | $-40.16M ▲ |
| Q1-2025 | $-43.64M ▲ | $-44.1M ▲ | $20.1M ▲ | $80.67M ▲ | $58.33M ▲ | $-44.23M ▲ |
| Q4-2024 | $-73.26M ▼ | $-52.84M ▼ | $-26.62M ▼ | $-6.52M ▲ | $-92.75M ▼ | $-52.91M ▼ |
| Q3-2024 | $-44.38M | $-36.6M | $47.67M | $-53.02M | $-37.96M | $-45.28M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration revenues | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License revenues | $0 ▲ | $0 ▲ | $10.00M ▲ | $0 ▼ |
CEO
Matthew Craig Kapusta CPA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 54
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Stifel
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Mizuho
Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
FMR LLC
Shares:6.06M
Value:$135.43M
AVORO CAPITAL ADVISORS LLC
Shares:4.44M
Value:$99.33M
RTW INVESTMENTS, LP
Shares:4.42M
Value:$98.9M
Summary
Showing Top 3 of 263